These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28065383)

  • 1. Molecular alterations contributing to pancreatic cancer chemoresistance.
    Rajabpour A; Rajaei F; Teimoori-Toolabi L
    Pancreatology; 2017; 17(2):310-320. PubMed ID: 28065383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
    Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
    Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
    Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance.
    Kaoutari AE; Fraunhoffer NA; Hoare O; Teyssedou C; Soubeyran P; Gayet O; Roques J; Lomberk G; Urrutia R; Dusetti N; Iovanna J
    EBioMedicine; 2021 Apr; 66():103332. PubMed ID: 33862584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.
    Garajová I; Le Large TY; Frampton AE; Rolfo C; Voortman J; Giovannetti E
    Biomed Res Int; 2014; 2014():678401. PubMed ID: 25250326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between microRNAs and chemoresistance in pancreatic cancer: Current knowledge, new insights, and forthcoming perspectives.
    Rahnama N; Jahangir M; Alesaeid S; Kahrizi MS; Adili A; Mohammed RN; Aslaminabad R; Akbari M; Özgönül AM
    Pathol Res Pract; 2022 Aug; 236():153982. PubMed ID: 35779293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-gene signaling pathways in pancreatic cancer.
    Drakaki A; Iliopoulos D
    Biomed J; 2013; 36(5):200-8. PubMed ID: 24225187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
    Nambaru PK; Hübner T; Köck K; Mews S; Grube M; Payen L; Guitton J; Sendler M; Jedlitschky G; Rimmbach C; Rosskopf D; Kowalczyk DW; Kroemer HK; Weiss FU; Mayerle J; Lerch MM; Ritter CA
    Drug Metab Dispos; 2011 Jan; 39(1):132-9. PubMed ID: 20930123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for advanced pancreatic cancer: a review.
    Warsame R; Grothey A
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1327-36. PubMed ID: 23176620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent studies of 5-fluorouracil resistance in pancreatic cancer.
    Wang WB; Yang Y; Zhao YP; Zhang TP; Liao Q; Shu H
    World J Gastroenterol; 2014 Nov; 20(42):15682-90. PubMed ID: 25400452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.
    Noma B; Sasaki T; Fujimoto Y; Serikawa M; Kobayashi K; Inoue M; Itsuki H; Kamigaki M; Minami T; Chayama K
    Int J Oncol; 2008 Dec; 33(6):1187-94. PubMed ID: 19020751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells.
    Huang B; Wang J; Chen Q; Qu C; Zhang J; Chen E; Zhang Y; Wang Y; Ni L; Liang T
    Am J Transl Res; 2019; 11(1):473-485. PubMed ID: 30788003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray analysis of gene expression profile of multidrug resistance in pancreatic cancer.
    Zhao YP; Chen G; Feng B; Zhang TP; Ma EL; Wu YD
    Chin Med J (Engl); 2007 Oct; 120(20):1743-52. PubMed ID: 18028764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance in pancreatic cancer: Impact of altered energy metabolism.
    Grasso C; Jansen G; Giovannetti E
    Crit Rev Oncol Hematol; 2017 Jun; 114():139-152. PubMed ID: 28477742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis.
    Garajová I; Le Large TY; Giovannetti E; Kazemier G; Biasco G; Peters GJ
    Methods Mol Biol; 2016; 1395():163-87. PubMed ID: 26910074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
    El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
    Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The promise of epigenomic therapeutics in pancreatic cancer.
    Lomberk GA; Iovanna J; Urrutia R
    Epigenomics; 2016 Jun; 8(6):831-42. PubMed ID: 27337224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review.
    Dhayat S; Mardin WA; Mees ST; Haier J
    Int J Cancer; 2011 Sep; 129(5):1031-41. PubMed ID: 21413017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated fibroblasts in pancreatic adenocarcinoma.
    Pan B; Liao Q; Niu Z; Zhou L; Zhao Y
    Future Oncol; 2015 Sep; 11(18):2603-10. PubMed ID: 26284509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noncoding RNAs in drug-resistant pancreatic cancer: A review.
    Lin Z; Lu S; Xie X; Yi X; Huang H
    Biomed Pharmacother; 2020 Nov; 131():110768. PubMed ID: 33152930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.